Method Development: Managing a diverse range of APIs
Tackling multiple challenges to support pre-clinical and GMP production
Starting from scratch: Designing custom analytics methods
CDMOs take on material at many different stages of development, and the design of analytic methods must account for thestarting conditions in each unique case. In this example, Avista Pharma adopted a drug substance that lacked available data from previous analytical studies or synthesis. Despite these barriers, they set out to develop analytical methods to support pre-clinical and future GMP production under tight timelines.
Because there was little known about the compound, the team designed methods to assess the starting material, intermediate material and API purity. Screening methods included pH, mobile phases, columns, gradients, and column temperature. Mass spectrometry was used to understand impurity formation so that it could be controlled in the API and starting materials.
Avista Pharma carefully designed methods for this API to be suitable and phase-appropriate for future GMP use. By defining the background for both starting material and process impurities, they were able to set GMP phase-appropriate specifications for starting materials, intermediates, and the API.
Impurities in the starting material and the API shared similar properties, making separation and retention a particular challenge. The custom analytical methods that were developed for this compound gave the client a method to derive PK and distribution data from pre-clinical samples, which was not attainable using their prior methods.
With reliable methods in place to support future GMP efforts, Avista Pharma secured two additional analytical projects with this client. No matter the state of the starting point, our talented experts are equipped to meet any challenge any deliver timely results.
Success beyond science.
Download a PDF of this case study.
Interested in learning more about Avista Pharma and how we can help you succeed? Contact Us